Cullinan Therapeutics, Inc. (CGEM) · Aug 12, 2026 · Other events

Zipalertinib clears its biggest hurdle—but the numbers are still hidden

Above the bar — Primary PFS endpoint met with statistically significant, clinically meaningful improvement

The Phase 3 first-line lung cancer trial hit its PFS endpoint at interim analysis, advancing approval hopes while leaving effect size and safety detail unknown.

The result arrives materially ahead of the expected timetable. Cullinan and Taiho had previously guided to REZILIENT3 topline results by the end of 2026, so an interim PFS readout on August 12, 2026 is earlier than the standing milestone.

The trial cleared its core success test. In the 285-patient Phase 3 study, zipalertinib plus platinum chemotherapy produced a statistically significant and clinically meaningful PFS improvement versus chemotherapy alone at planned interim analysis, prompting the independent monitoring committee to recommend unblinding. The trial continues for further efficacy and safety follow-up. (About the REZILIENT3 Trial)

This is better than a mere “trial ongoing” update, but the filing withholds the numbers that determine magnitude. It provides no hazard ratio, median PFS, confidence interval, overall-survival result, or detailed adverse-event table. “Manageable” safety is encouraging but cannot yet establish how the regimen compares on tolerability. (REZILIENT3 topline results)

Net read: above the clinical bar and meaningfully de-risks the first-line opportunity. The positive interim result supports plans to pursue U.S. approval for the combination, but the investment case still depends on the full dataset, regulatory feedback, and whether the eventual PFS benefit is large and durable enough to change treatment practice. (REZILIENT3 topline results)

What to watch next

Full REZILIENT3 data presentation and FDA regulatory discussions

Original filing on SEC EDGAR

More Cullinan Therapeutics, Inc. news

Zipalertinib clears its biggest hurdle—but the numbers are still hidden | CGEM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.